Azumamide E

Overview

Azumamide E is a HDAC inhibitor, with an IC 50 of 0.064 μM against HDAC , 1.22 μM against HDAC1 , and 2.28 μM against HDAC4 . Azumamide E inhibits HDAC activity in nuclear extracts of leukemia cells and cervical adenocarcinoma cells. Azumamide E suppresses angiogenesis. Azumamide E is applicable for research on leukemia, cervical adenocarcinoma, and anti-angiogenesis.

Application

Products | Products > Peptides | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Cervical Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HDAC

Product Information

• Catalog No.: HY-P2044
• CAS No.: 585535-37-1
• Molecular Formula: C27H38N4O6
• Molecular Weight: 514.62
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source